Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine.

Mediators of inflammation - 1 Jan 2014

Daïen Claire I, Morel Jacques

Abstract excerpt

Many therapies are now available for patients with rheumatoid arthritis (RA) who have an inadequate response to methotrexate including tumor necrosis factor inhibitors, abatacept, tocilizumab, and rituximab. Clinical response to drugs varies widely between individuals. A part of this variability is due to the characteristics of the patient such as age, gender, concomitant therapies, body mass index, or smoking...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Abatacept
Share to Antibodies, Monoclonal, Murine-Derived
Share to Antirheumatic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biological Products

Share to Immunoconjugates

Share to Methotrexate

Share to Remission Induction

Share to Rituximab

Source

Open in PubMed Open full text

Identifiers

PMID: 24523570
DOI: 10.1155/2014/386148
PMCID: PMC3913459

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine.PMID 24523570Read ↗

Biomarkers to Personalize the Treatment of Rheumatoid Arthritis: Focus on Autoantibodies and PharmacogeneticsSemantic proximity Read ↗

Prediction of Response to Targeted Treatment in Rheumatoid Arthritis.Semantic proximity Read ↗

Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted?Semantic proximity Read ↗

The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy.Semantic proximity Read ↗

[Predictors of response to biologic therapies in rheumatoid arthritis].Semantic proximity Read ↗

Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response.Semantic proximity Read ↗

Pharmacogenomics of biological treatment in rheumatoid arthritis.Semantic proximity Read ↗

Pharmacogenomics of Anti-TNF Treatment Response Marks a New Era of Tailored Rheumatoid Arthritis Therapy.Semantic proximity Read ↗

Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine.Semantic proximity Read ↗

Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis.Semantic proximity Read ↗

The evolution of biomarkers in rheumatoid arthritis: from clinical research to clinical care.Semantic proximity Read ↗

Personalized medicine in rheumatoid arthritis: hopes and challenges.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.